Neeraja Kulkarni

Inflection Point Ventures was started in 2018 with the aim of driving exponential value creation by being India’s most accessible & efficient network connecting a diverse investor community with a carefully set of curated startups. IPV is an early-stage angel investing platform, which provides both monetary and non-monetary support to the startups, as well as complete transparency around valuation, findings during due diligence, and personal interest (if any) to its investors. Today, it has 14,000+ angel investors, with the community having expanded beyond CXOs to include HNIs who come from varied backgrounds, professions and areas of expertise. IPV caters to investors pan India, and overseas, giving them access to startups and deals, making the group location and region agnostic. Since inception, we have invested in 250+ startups, with more in advanced stages of negotiations. IPV evaluation process screens startups and presents to investors only those, we feel have the potential to scale up. Till date we have considered startups spanning various industries such as Healthcare, Sports and Fitness, Retail Finance, HR, AI in hiring, Education, Supply Chain and Logistics etc, which shows that we do not have any predefined restrictions. For more information please visit our website.

Inflection Point Ventures was started in 2018 with the aim of driving exponential value creation by being India’s most accessible & efficient network connecting a diverse investor community with a carefully set of curated startups. IPV is an early-stage angel investing platform, which provides both monetary and non-monetary support to the startups, as well as complete transparency around valuation, findings during due diligence, and personal interest (if any) to its investors. Today, it has 14,000+ angel investors, with the community having expanded beyond CXOs to include HNIs who come from varied backgrounds, professions and areas of expertise. IPV caters to investors pan India, and overseas, giving them access to startups and deals, making the group location and region agnostic. Since inception, we have invested in 250+ startups, with more in advanced stages of negotiations. IPV evaluation process screens startups and presents to investors only those, we feel have the potential to scale up. Till date we have considered startups spanning various industries such as Healthcare, Sports and Fitness, Retail Finance, HR, AI in hiring, Education, Supply Chain and Logistics etc, which shows that we do not have any predefined restrictions. For more information please visit our website.

ImmunoScape is a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR cell therapies in the field of oncology. The companys proprietary Deep Immunomics technology platform enables highly sensitive, large-scale mining and immune profiling of T cells in cancer patient samples to identify novel, therapeutically relevant TCRs across multiple types of solid tumors. ImmunoScape has multiple discovery programs ongoing and will be progressing towards IND-enabling studies and entry into the clinic. To learn more, visit us at immunoscape.com and follow us on Twitter @immunoscape.